A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models.
John O DaSilvaKatie YangAndres E Perez BayJulian AndreevPeter NgoiErica PylesMatthew C FranklinDrew DudgeonAshique RafiqueAnthony DoreFrank J DelfinoTerra B PotockyRobert BabbGang ChenDouglas MacDonaldWilliam C OlsonGavin ThurstonChristopher DalyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Our results provide strong support for the notion that biparatopic antibodies are a promising therapeutic modality, potentially having greater efficacy than that predicted from the properties of the parental antibodies.
Keyphrases